Published in FEBS Lett on July 22, 1996
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A (1998) 2.71
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol (1999) 1.65
The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology (2013) 1.56
Fast synaptic inhibition in spinal sensory processing and pain control. Physiol Rev (2012) 1.45
Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci U S A (2000) 1.32
Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest (2005) 1.30
The spinal biology in humans and animals of pain states generated by persistent small afferent input. Proc Natl Acad Sci U S A (1999) 1.27
Involvement of bradykinin, cytokines, sympathetic amines and prostaglandins in formalin-induced orofacial nociception in rats. Br J Pharmacol (2004) 1.10
Sensory nerves have altered function contralateral to a monoarthritis and may contribute to the symmetrical spread of inflammation. Eur J Neurosci (2007) 1.02
Intervention of electroacupuncture on spinal p38 MAPK/ATF-2/VR-1 pathway in treating inflammatory pain induced by CFA in rats. Mol Pain (2013) 0.98
MK801 attenuates secondary injury in a mouse experimental compression model of spinal cord trauma. BMC Neurosci (2011) 0.96
Rat pulmonary cyclooxygenase-2 expression in response to endotoxin challenge: differential regulation in the various types of cells in the lung. Am J Pathol (2000) 0.95
Aspirin and other anti-inflammatory drugs. Thorax (2000) 0.93
Rationally designed multitarget agents against inflammation and pain. Curr Med Chem (2013) 0.91
The role of spinal neuropeptides and prostaglandins in opioid physical dependence. Br J Pharmacol (2002) 0.86
Transcutaneous electrical nerve stimulation attenuates CFA-induced hyperalgesia and inhibits spinal ERK1/2-COX-2 pathway activation in rats. BMC Complement Altern Med (2013) 0.86
Constitutive cyclooxygenase-2 is involved in central nociceptive processes in humans. Anesthesiology (2007) 0.85
Effect of selective inhibition of cyclooxygenase-2 on lipopolysaccharide-induced hyperalgesia. Inflammopharmacology (2004) 0.84
Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. Biochem J (2005) 0.84
In vitro prostanoid release from spinal cord following peripheral inflammation: effects of substance P, NMDA and capsaicin. Br J Pharmacol (1999) 0.84
Risk management profile of etoricoxib: an example of personalized medicine. Ther Clin Risk Manag (2008) 0.81
[From willow bark to the coxibs. Development of antiphlogistic analgesics]. Schmerz (2007) 0.81
Co-induction of cyclooxygenase-2 [correction of cyclooxyenase-2] and early growth response gene (Egr-1) in spinal cord in a clinical model of persistent inflammation and hyperalgesia. Mol Pain (2011) 0.79
Cyclooxygenase-2 inhibitors: promise or peril? Mediators Inflamm (2002) 0.79
Roles of serotonergic and adrenergic receptors in the antinociception of selective cyclooxygenase-2 inhibitor in the rat spinal cord. Korean J Pain (2011) 0.78
Role of prostaglandins in spinal transmission of the exercise pressor reflex in decerebrated rats. Neuroscience (2014) 0.78
Resveratrol attenuates inflammation-induced hyperexcitability of trigeminal spinal nucleus caudalis neurons associated with hyperalgesia in rats. Mol Pain (2016) 0.77
EP1 receptor within the ventrolateral periaqueductal grey controls thermonociception and rostral ventromedial medulla cell activity in healthy and neuropathic rat. Mol Pain (2011) 0.77
Parecoxib sodium in the treatment of postoperative pain after Lichtenstein tension-free mesh inguinal hernia repair. Hernia (2010) 0.77
Effects of Parecoxib and Fentanyl on nociception-induced cortical activity. Mol Pain (2010) 0.77
Modulatory Mechanism of Nociceptive Neuronal Activity by Dietary Constituent Resveratrol. Int J Mol Sci (2016) 0.76
Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam. Inflamm Res (2010) 0.76
Interactions of estradiol and NSAIDS on carrageenan-induced hyperalgesia. Brain Res (2011) 0.76
Cdk5: An Emerging Kinase in Pain Signaling. Brain Disord Ther (2012) 0.75
NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals (Basel) (2010) 0.75
Dipyrone & 2,5-dimethylcelecoxib suppress Th2-related chemokine production in monocyte. Indian J Med Res (2014) 0.75
Pyrimidine nucleotide-stimulated thromboxane A2 release from cultured glia. Cell Mol Neurobiol (1998) 0.75
Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J (2001) 2.52
Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. J Rheumatol (1995) 2.09
COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J (2001) 1.97
Assessment of phagocytic and antimicrobial activity of human granulocytes. Infect Immun (1974) 1.96
Quantitative detection of Borrelia burgdorferi by real-time PCR. J Clin Microbiol (1999) 1.93
The venous graft as an effector of early angiogenesis in a fibrin matrix. Microvasc Res (2007) 1.93
Women encounter ADRs more often than do men. Eur J Clin Pharmacol (2008) 1.83
Gastrointestinal ulcerations induced by anti-inflammatory drugs in rats. Physicochemical and biochemical factors involved. Arch Toxicol (1990) 1.59
Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf (2000) 1.51
Pharmacological control of prostaglandin and thromboxane release from macrophages. Nature (1978) 1.44
Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med (2004) 1.42
Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol (2000) 1.42
Peroxidaseless chicken leukocytes: isolation and characterization of antibacterial granules. J Infect Dis (1973) 1.39
Inhibition of anti-inflammatory drugs of prostaglandin production in cultured macrophages. Naunyn Schmiedebergs Arch Pharmacol (1981) 1.36
Leukocytes and prostaglandins in acute inflammation. Experientia (1974) 1.35
Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet (1999) 1.32
Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol (1997) 1.28
Computerized surveillance of adverse drug reactions in hospital: implementation. Eur J Clin Pharmacol (1999) 1.24
Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. J Am Soc Nephrol (2001) 1.22
Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. J Biol Chem (2000) 1.21
Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J (2001) 1.18
Possible role of oxygen free radicals in ethanol-induced gastric mucosal damage in rats. Dig Dis Sci (1988) 1.17
Inhibition of cyclooxygenases by dipyrone. Br J Pharmacol (2007) 1.14
Biodistribution of mild analgesics. Br J Clin Pharmacol (1980) 1.12
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther (2002) 1.12
Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost (2011) 1.11
Acidic nonsteroid anti-inflammatory drugs accumulating in inflamed tissue. Experientia (1975) 1.11
Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. Neuroscience (2004) 1.10
Microbicidal activity of peroxidaseless chicken heterophile leukocytes. Infect Immun (1972) 1.10
Correlation between antimicrobial activity and peroxidase content of leukocytes. Nature (1973) 1.10
Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol (1999) 1.10
Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth (1993) 1.10
The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther (1999) 1.08
Prostaglandin release from macrophages: an assay system for anti-inflammatory drugs in vitro. Agents Actions (1977) 1.08
Prostaglandin E(2) upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun (2000) 1.08
Effect of anti-inflammatory and analgesic pyrazoles on arachidonic acid metabolism in isolated heart and gastric mucosa preparations. Agents Actions Suppl (1986) 1.07
Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related evoked potentials and vigilance in relationship to pharmacokinetic parameters. Agents Actions (1990) 1.06
Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br J Clin Pharmacol (1994) 1.05
Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. Am J Respir Cell Mol Biol (1998) 1.04
Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation (2001) 1.04
Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy. Drugs (1991) 1.04
Signal transduction pathways responsible for serotonin-mediated prostaglandin G/H synthase expression in rat mesangial cells. J Biol Chem (1994) 1.04
Control of prostanoid synthesis: role of reincorporation of released precursor fatty acids. Prostaglandins (1986) 1.03
Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol (1992) 1.02
The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. Anesthesiology (2001) 1.02
Pure enantiomers of 2-arylpropionic acids: tools in pain research and improved drugs in rheumatology. J Clin Pharmacol (1992) 1.02
Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Clin Pharmacol Ther (1999) 1.01
Interleukin-1beta induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells. J Biol Chem (2001) 1.01
Serum antibodies against chondrocyte cell surface proteins in osteoarthritis and rheumatoid arthritis. J Rheumatol (1988) 1.01
Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord. J Neurochem (2001) 1.00
Computerized survelliance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol (1998) 1.00
Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol (2001) 1.00
Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. Arthritis Rheum (2001) 1.00
Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS-deficient mice. J Neurosci (2000) 0.99
Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E(2), and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun (2000) 0.99
Effects of pure enantiomers of flurbiprofen in comparison to racemic flurbiprofen on eicosanoid release from various rat organs ex vivo. Prostaglandins (1991) 0.99
Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia (1991) 0.99
Inflammatory models of cutaneous hyperalgesia are sensitive to effects of ibuprofen in man. Pain (1995) 0.98
Non-acidic pyrazoles: inhibition of prostaglandin production, carrageenan oedema and yeast fever. Agents Actions (1983) 0.98
Role of the parietal cell in gastric damage induced by aspirin and related drugs: implications for safer therapy. Med J Aust (1976) 0.97
How aspirin might work: a pharmacokinetic approach. Agents Actions (1974) 0.97
Differential opioid action on sensory and affective cerebral pain processing. Clin Pharmacol Ther (2007) 0.97
Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int (1994) 0.97
Effects of glucocorticoids on the TPA-induced monocytic differentiation. J Leukoc Biol (1992) 0.97
Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther (2001) 0.96
Dose-related effects of ibuprofen on pain-related potentials. Br J Clin Pharmacol (1994) 0.96
Non-steroid anti-inflammatory drugs: influence of extra-cellular pH on biodistribution and pharmacological effects. Biochem Pharmacol (1978) 0.95
Release of algesic substances in human experimental muscle pain. Inflamm Res (2002) 0.95
Rat pulmonary cyclooxygenase-2 expression in response to endotoxin challenge: differential regulation in the various types of cells in the lung. Am J Pathol (2000) 0.95
[Treatment of tension-type headache. Recommendation of the German Migraine and Headache Society]. Schmerz (1998) 0.95
Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol (1989) 0.95
Pharmacokinetics of S(+)- and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis. Eur J Clin Pharmacol (1990) 0.94
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther (1999) 0.94
Ibuprofen as an over-the-counter drug: is there a risk for renal injury? Clin Nephrol (1993) 0.94
Modulation of spinal nociceptive processing through the glutamate transporter GLT-1. Neuroscience (2003) 0.94
High-performance liquid chromatographic determination of ibuprofen, its metabolites and enantiomers in biological fluids. J Chromatogr (1989) 0.94
Peripheral antihyperalgesic effect of morphine to heat, but not mechanical, stimulation in healthy volunteers after ultraviolet-B irradiation. Anesth Analg (1999) 0.93
Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest Ophthalmol Vis Sci (2001) 0.93
Implementation of a computer-assisted monitoring system for the detection of adverse drug reactions in gastroenterology. Aliment Pharmacol Ther (2004) 0.93
Purification of human leukotriene C4 synthase. Proc Natl Acad Sci U S A (1992) 0.93
Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. Hypertension (1998) 0.93
Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J (2006) 0.93
Stereoselective high-performance liquid chromatographic determination of flurbiprofen in human plasma. J Chromatogr (1992) 0.93
Mechanisms of action of anti-inflammatory drugs. Gen Pharmacol (1976) 0.93
Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J (2000) 0.92
Identification and characterization of inhibitors of peptido-leukotriene-synthesis from Petasites hybridus. Planta Med (1994) 0.92
The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain. Clin Pharmacol Ther (2008) 0.92
Spinally delivered nociceptin/orphanin FQ reduces flinching behaviour in the rat formalin test. Neuroreport (1997) 0.92